AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 08/29/23

- Senior members of the U.S. Government Visit One of Amneal’s 12 Manufacturing Sites Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that a delegation of senior members of the U.S. Department of Health and Human ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston. Mr. Pat...

- IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study ...

2023-08-21 16:01:59 ET Are you on the hunt for the most promising penny stocks to invest in for 2023? Join the ever-expanding group of investors who are keen to leverage the booming market. With record-breaking performances by the S&P 500 and Nasdaq this year, there’s a growi...

2023-08-07 14:08:45 ET Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation ...

2023-08-04 15:59:06 ET Amneal Pharmaceuticals, Inc. (AMRX) Q2 2023 Earnings Conference Call August 4, 2023 08:30 ET Company Participants Anthony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder an...

2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...

2023-08-04 06:03:20 ET Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q2 Non-GAAP EPS of $0.19 beats by $0.09 . Revenue of $599M (+7.2% Y/Y) beats by $33.89M . FY23 Outlook: Net revenue of $2.3B-$2.4B from prior guidance of $2.25-$2.35B Adj EPS of...

‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Fu...

2023-08-03 14:20:38 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q2 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is $0.10 (-47.4% Y/Y) and the consensus Revenue Estimate is $565.11M (+1.1% Y/Y). Over the la...